Public Release: 

New treatments help those with mild, moderate and severe eczema

Both children and adults benefit from new approaches

American College of Allergy, Asthma, and Immunology

BOSTON, MA (Oct. 27, 2017) - If you think only infants suffer from eczema, think again. The uncomfortable, itchy rash that most people relate to babies and young children occurs frequently in adults. Although many adults with atopic dermatitis (commonly known as eczema) develop the disease in childhood and carry it through life, a large number are first diagnosed in adulthood - a trend being discussed at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting.

"Atopic dermatitis (AD) is underdiagnosed in the United States," says allergist Luz Fonacier, MD, ACAAI board member and presenter at the meeting. "Many adults don't seek out medical care, preferring to self-treat instead, either with home remedies or over-the-counter drugs. Often, they aren't aware they have eczema, and they also don't know treatments have changed a lot in the last few years. There are new drugs and topical medications that can make a huge difference in their quality of life."

In addition to the itching and discomfort, people with eczema can experience problems with sleep and emotional distress, and it can affect their social life. Allergists work with patients to introduce therapies that treat uncomfortable and sometimes painful symptoms like dry skin, itchiness, and scaly rashes that can become infected. Easing the discomfort associated with painful symptoms can improve quality of life and make sleeping easier, as well as relieve emotional distress and embarrassment.

"In the last few years we've seen the introduction of targeted therapies, also known as precision medicine," says allergist Mark Boguniewicz, MD, ACAAI member and lead author on a soon-to-be-published Atopic Dermatitis Yardstick. "The Yardstick will have practical recommendations for physicians about the treatment of AD."

Two new medications have recently been approved for AD. The first, crisaborole, is an ointment that reduces itching, redness and swelling of the skin. It is the first anti-inflammatory medication to be approved for the treatment of mild to moderate AD in more than 15 years. It is approved for patients 2 years of age or older. Dupilumab, the second new medication, is a biologic therapy given by injection for patients 18 years or older with moderate to severe AD who haven't responded to, or can't use topical medications.

"The takeaway message is that there are effective medications available that help relieve eczema symptoms and now can also target the underlying cause," says Dr. Boguniewicz. "People with eczema have been frustrated by the limitations of existing treatments. We're very excited by the new medications which were developed based on better understanding of atopic dermatitis. We expect additional therapies to be approved soon. An allergist has the right training and expertise to diagnose your eczema, and to help you find relief with the right treatments."

###

Workshop Title: Moving Toward Precision Medicine in Atopic Dermatitis

Presenters: Luz Fonacier, MD, FACAAI, Mark Boguniewicz, MD, FACAAI

For more information about allergies and eczema, and to locate an allergist in your area, visit AllergyandAsthmaRelief.org. The ACAAI Annual Scientific Meeting is October 26-30, 2017 at the Hynes Convention Center in Boston, MA. For more news and research from the ACAAI Annual Scientific Meeting, go to our press kit - and follow the conversation on Twitter #ACAAI17.

About ACAAI

The ACAAI is a professional medical organization of more than 6,000 allergists-immunologists and allied health professionals, headquartered in Arlington Heights, Ill. The College fosters a culture of collaboration and congeniality in which its members work together and with others toward the common goals of patient care, education, advocacy and research. ACAAI allergists are board-certified physicians trained to diagnose allergies and asthma, administer immunotherapy, and provide patients with the best treatment outcomes. For more information and to find relief, visit AllergyandAsthmaRelief.org. Join us on Facebook, Pinterest and Twitter.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.